Axsome Therapeutics, Inc.
Axsome Therapeutics, Inc.
Explore linked clinical trials.14 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| SUNOSI® (Solriamfetol) Pregnancy Registry | Apnea, Disorders of Excessive Somnolence, Dyssomnias, Respiration Disorders, Sleep Disorders, Intrinsic, narcolepsy, nervous system disorder, obstructive sleep apnea syndrome, psychiatric disorder, respiratory system disorder, sleep apnea syndrome, sleep-wake disorder | Recruiting | Not stated | 2026-10-05 | NCT06413420 | |
| An Open-Label Study to Assess the Long-Term Safety of Solriamfetol in Children and Adolescents With ADHD | attention deficit hyperactivity disorder, inattentive type, neurodevelopmental disorder, oppositional defiant disorder, psychiatric disorder | Enrolling by invitation | Phase 3 | 2026-09-08 | NCT07773883 | |
| Studying NMDA and Sigma-1 in Smoking Cessation Treatment (SUMMIT) | Smoking Cessation | Recruiting | Phase 3 | 2026-09-08 | NCT07766655 | |
| Forward Treatment of Attention Deficit and Hyperactivity Using Solriamfetol (FOCUS-3) | attention deficit hyperactivity disorder, inattentive type, neurodevelopmental disorder, oppositional defiant disorder, psychiatric disorder | Recruiting | Phase 3 | 2026-09-08 | NCT07717892 | |
| Forward Treatment of Attention Deficit and Hyperactivity Using Solriamfetol (FOCUS-2) | attention deficit hyperactivity disorder, inattentive type, neurodevelopmental disorder, oppositional defiant disorder, psychiatric disorder | Recruiting | Phase 3 | 2026-09-08 | NCT07717879 | |
| Open-Label Safety Study of AXS-14 in Subjects With Fibromyalgia | Hyperalgesia, Neurologic Manifestations, Pathological Conditions, Signs and Symptoms, Sensation Disorders, Signs and Symptoms, Somatosensory Disorders, fibromyalgia, muscle tissue disorder, musculoskeletal system disorder, nervous system disorder, neuromuscular disease, rheumatic disorder | Enrolling by invitation | Phase 3 | 2026-09-04 | NCT07637162 | |
| Fibromyalgia Response With Esreboxetine Evaluated Using a Randomized Withdrawal Research Design | Hyperalgesia, Neurologic Manifestations, Pathological Conditions, Signs and Symptoms, Sensation Disorders, Signs and Symptoms, Somatosensory Disorders, fibromyalgia, muscle tissue disorder, musculoskeletal system disorder, nervous system disorder, neuromuscular disease, rheumatic disorder | Recruiting | Phase 3 | 2026-09-04 | NCT07398417 | |
| A Study to Assess the Long-term Safety and Efficacy of Solriamfetol in Subjects With Binge Eating Disorder | Binge-Eating Disorder, Feeding and Eating Disorders, psychiatric disorder | Enrolling by invitation | Phase 3 | 2026-08-11 | NCT06878976 | |
| Elucidating TAAR-1, Dopamine, and Norepinephrine in Binge Eating Disorder Using Solriamfetol | Binge-Eating Disorder, Feeding and Eating Disorders, psychiatric disorder | Recruiting | Phase 3 | 2026-07-28 | NCT06413433 | |
| Clinical Assessment of Response in the Treatment of Depression With Daytime Sleepiness Using Solriamfetol | Disorders of Excessive Somnolence, Dyssomnias, Sleep Disorders, Intrinsic, depressive disorder, major depressive disorder, mood disorder, nervous system disorder, psychiatric disorder, sleep-wake disorder | Recruiting | Phase 3 | 2026-07-24 | NCT07484217 | |
| Studying Solriamfetol Modulation of TAAR-1, Dopamine, and Norepinephrine in Shift Work Disorder (SUSTAIN) | Chronobiology Disorders, Disorders of Excessive Somnolence, Dyssomnias, Occupational Diseases, Sleep Disorders, Intrinsic, circadian rhythm sleep disorder, insomnia, nervous system disorder, psychiatric disorder, sleep-wake disorder | Recruiting | Phase 3 | 2026-07-24 | NCT06568367 | |
| Solriamfetol for the Treatment of Multiple Sclerosis Fatigue | CNS demyelinating autoimmune disease, Disorders of Excessive Somnolence, Dyssomnias, Fatigue, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, Sleep Disorders, Intrinsic, autoimmune disease, autoimmune disorder of the nervous system, demyelinating disease, immune system disorder, multiple sclerosis, nervous system disorder, psychiatric disorder, sleep-wake disorder | Recruiting | Phase 2 | 2026-06-09 | NCT06170970 | |
| Dextromethorphan-Bupropion on Striatal Activity in Adults With Major Depressive Disorder | depressive disorder, major depressive disorder, mood disorder, psychiatric disorder | Recruiting | Phase 2 | 2026-04-13 | NCT07523048 | |
| A Study to Evaluate the Efficacy of AXS-05 Compared to Bupropion in Preventing the Relapse of Depressive Symptoms | depressive disorder, major depressive disorder, mood disorder, psychiatric disorder | Recruiting | Phase 4 | 2025-01-23 | NCT06223880 |